Summary of Precigen (PGEN) Q3 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: As of September 30, 2025, Precigen reported $123.6 million in cash, cash equivalents, and investments.

Inventory: Approximately $3 million in inventory related to Papcemias manufacturing costs post-approval.

Net Loss: The net loss attributable to common shareholders for the quarter was $1.06 per share, which included $0.95 per share from non-cash accounting items (warrant liability change and preferred shares conversion).

SG&A Expenses: Increased by approximately $14 million due to commercialization efforts for Papcemias.

Revenue Recognition: Revenue from Papcemias is recognized upon transfer of title to the shipping entity, not at the time of patient injection.

2Strategic Updates and Business Highlights

Product Approval: Papcemias received full FDA approval in August 2025 as the first and only treatment for adult recurrent respiratory papillomatosis (RRP).

Clinical Efficacy: 51% of patients achieved complete response (no surgery for 12 months), with 86% showing reduced surgical burden.

Commercial Launch: A sales team of 18 key account managers was deployed in September, engaging with 90% of target institutions covering a significant portion of the 27,000 adult RRP patients.

Payer Coverage: Over 80 million lives covered, including Medicare and Medicaid, with multiple formulary approvals achieved.

International Expansion: A marketing authorization application has been submitted to the EMA for geographic expansion.

3Forward Guidance and Outlook

Cash Flow Breakeven: The company expects to reach cash flow breakeven by 2026, supported by projected revenues from Papcemias.

Patient Demand: Anticipated strong uptake from the existing patient population and new diagnoses, with a focus on early intervention to prevent surgeries.

Redosing Potential: Future data generation on redosing is planned, as FDA encourages this based on safety and efficacy results.

4Bad News, Challenges, or Points of Concern

Increased Operating Expenses: The rise in SG&A costs reflects the significant investment in commercialization efforts, which could pressure profitability in the short term.

Non-Cash Losses: The substantial net loss includes significant non-cash items, which may obscure the underlying financial health.

Reimbursement Hurdles: Initial reimbursement processes may slow patient access to treatment, although the company is optimistic about overcoming these challenges.

5Notable Q&A Insights

Patient Dosing: The company refrained from disclosing specific patient dosing numbers but indicated that they expect significant patient treatment activity in Q4 2025.

Patient Hub Dynamics: There is a dual hub system for patient registration, with both the Precigen hub and institutional hubs actively processing patients.

Market Demand: There is strong enthusiasm from healthcare providers for Papcemias, indicating robust market demand and potential for rapid patient enrollment.

Revenue Projections: While specific revenue guidance was not provided, management expressed confidence in reaching cash flow breakeven based on anticipated patient uptake and market dynamics. Overall, Precigen is positioned for growth following the successful launch of Papcemias, with strong clinical data and a supportive market environment, despite facing challenges related to commercialization costs and reimbursement processes.